<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118581</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-10-25</org_study_id>
    <nct_id>NCT05118581</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ultrasound Guided Vascular Access</brief_title>
  <official_title>Safety and Efficacy of Ultrasound Guided Vascular Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular access involves central and peripheral vein accesses and arterial accesses. Central&#xD;
      venous catheterization is widely used in clinical practice for diverse purposes, including&#xD;
      hemodialysis for end stage renal failure, invasive hemodynamic monitoring, radiological&#xD;
      studies, infusion of drugs that cannot be administered via peripheral vessels, administration&#xD;
      of parenteral nutrition, vascular access in patients whose peripheral veins are difficult to&#xD;
      be catheterized and for miscellaneous purposes that require access to large caliber vessels.&#xD;
&#xD;
      Arterial cannulation is used for invasive arterial pressure monitoring and to ensure access&#xD;
      for diagnostic and therapeutic interventions.&#xD;
&#xD;
      In the United States and United Kingdom, guidelines have recommended the use of ultrasound&#xD;
      guidance to reduce complications and improve success in central venous catheterization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse effects of ultrasound guided vascular access</measure>
    <time_frame>one year</time_frame>
    <description>Number of participants with adverse effects after ultrasound guided vascular access</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vascular Access</condition>
  <condition>Ultrasound Guided Vascular Access</condition>
  <arm_group>
    <arm_group_label>patients need vascular access</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arterial or venous cathetrization guided by ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ultrasound guided vascular access</intervention_name>
    <description>Arterial or venous catheterization guided by ultrasound</description>
    <arm_group_label>patients need vascular access</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  · Adult patients who need vascular access (arterial or venous)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  · Patients with local infection in the area targeted for vascular access.&#xD;
&#xD;
               -  Patients with severe generalized infection and other skin diseases or lesions.&#xD;
&#xD;
               -  patients with history of DVT of the target vein and or pulmonary embolism.&#xD;
&#xD;
               -  Patients with untreated coagulopathy (INR &gt;1.5 or platelets &lt;50000mm3)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mostafa M Ahmed, resident</last_name>
    <phone>01004115144</phone>
    <phone_ext>002</phone_ext>
    <email>mostafaelsayed@med.sohag.edu.eg</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 13, 2021</last_update_submitted>
  <last_update_submitted_qc>November 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Mostafa Ahmed Elsayed</investigator_full_name>
    <investigator_title>resident doctor at vascular surgery department sohag university hospital</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

